NeoGenomics saw the highest growth of 0.99% in patent filings and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.99% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of NeoGenomics‘s patent filings and grants. Buy the databook here.
NeoGenomics has been focused on protecting inventions in United States(US) with three publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 100% filings and 100% grants. The United States(US) patent Office are among the top ten patent offices where NeoGenomics is filings its patents. Among the top granted patent authorities, NeoGenomics has 100% of its grants in United States(US).
Regeneron Pharmaceuticals and Immatics could be the strongest competitors for NeoGenomics
Patents related to genomics lead NeoGenomics's portfolio
NeoGenomics has the highest number of patents in genomics. For genomics, nearly 100% of patents were filed and no patents were granted in Q2 2024.
Digital signal processors(dsp) related patents lead NeoGenomics portfolio
NeoGenomics has highest number of patents in digital signal processors(dsp).
For comprehensive analysis of NeoGenomics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.